Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil and finasteride have not improved the user's hairline after a year. Suggestions include trying dutasteride, microneedling, or considering a hair transplant for better results.

A 26-year-old is considering switching from a regimen of minoxidil, finasteride, and RU58841 to possibly include pyrilutamide due to insufficient results in slowing hair loss. They are seeking advice on whether to add pyrilutamide or replace RU58841 with it, considering cost and effectiveness.

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

A new alcohol-free, propylene glycol-free topical finasteride foam is available for prescription in Canada and the USA, offering a cleaner alternative for hair loss treatment. The product also offers a combination of 0.1% finasteride with 5% minoxidil and aims to be affordable and less irritating for sensitive scalps.

A 22-year-old male experienced significant hair regrowth after five months using 1mg finasteride and 5mg minoxidil, with plans to switch to dutasteride. He reported emotional changes and thicker eyebrows and eyelashes as side effects.

The user started shedding hair after beginning testosterone replacement therapy (TRT) despite using dutasteride and minoxidil, and added RU58841 to address the shedding. They reduced their TRT dose and hope RU58841 will stop the shedding quickly.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

The user is using oral minoxidil, ghk-cu, and HGH for hair regrowth, noticing small vellus hairs on the crown. They avoid traditional DHT blockers like finasteride due to side effects, despite skepticism from others about the effectiveness of ghk-cu.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

High-dose oral minoxidil (>5 mg/day) can increase hair density in some men with androgenetic alopecia, but side effects like extra body hair and heart issues are common. Gradual dose increase is advised, but adverse effects may lead to discontinuation or dose adjustments.

Minoxidil and Nizoral alone are unlikely to stop hair loss effectively, as they do not address the root cause, which is often DHT. Many users suggest incorporating a 5AR inhibitor like finasteride or dutasteride for better results, despite concerns about potential side effects.

The user experienced decreased libido with saw palmetto and is now considering topical anti-androgens like RU58841, pyrilutamide, and topical dutasteride for hair loss. Minoxidil is also mentioned as a potential addition, but the user is cautious about side effects and availability of treatments.

A 22-year-old is considering starting finasteride for hair loss, questioning if their hairline is stable or if treatment is needed. They shared images of their hairline, which has been the same since their teenage years.

Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.

A 22-year-old shared his 15-month progress using finasteride and 12-month progress with minoxidil for hair loss, noting improved thickness but minimal hairline change. He experienced initial shedding with minoxidil but no side effects from finasteride, and he advises patience and consistency for results.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

A 23-year-old discusses their hair loss treatment using finasteride, dutasteride, oral and topical minoxidil, and topical tretinoin under medical supervision. They stress stabilizing hair loss before a hair transplant and plan to continue the regimen for at least 18 months.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

Fucoidan may help regrow hair and reduce inflammation in androgenetic alopecia. It is unclear if simply mixing fucoidan powder into a serum for application is effective.

The user used microneedling, zinc, vitamin D3, biotin, magnesium, saw palmetto, pumpkin seed oil, and a DHT-blocker shampoo with biotin for hair loss. They are considering adding minoxidil due to stagnation in progress.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The user shared their hair regrowth progress using a regimen including omega-3, flaxseed, EGCG, green tea, zinc, copper, probiotics, microneedling, topical finasteride, and minoxidil. Other users expressed skepticism about the effectiveness of the regimen, suggesting more proven treatments or considering a hair transplant.

A 23-year-old male has been using Dutasteride for 10 months, alongside topical Minoxidil and Ketoconazole, but is experiencing increased hair thinning, particularly at the crown. Despite trying different dosages and treatments, including a brief attempt with oral Minoxidil, the user is frustrated with the lack of improvement and is seeking advice from others with similar experiences.

Oral minoxidil is gaining popularity due to increased awareness and convenience, despite potential side effects like cardiac issues and unwanted hair growth. Users report mixed results, with some seeing significant regrowth and others experiencing side effects or minimal improvement.